Influenza

Infectious Disease MONDO:0005812 Viral Respiratory Infection

Influenza is an acute respiratory infectious disease caused by influenza viruses (types A and B in humans), transmitted via respiratory droplets. Influenza A and B cause seasonal epidemics, while influenza A is responsible for pandemics due to antigenic shift. The WHO estimates annual epidemics result in approximately 1 billion infections, 3-5 million cases of severe illness, and 300,000-500,000 deaths globally. The disease ranges from mild upper respiratory illness to severe pneumonia, acute respiratory distress syndrome, and death, particularly in elderly, immunocompromised, and young populations.

Ask OpenScientist

Ask a research question about Influenza. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
10
Phenotypes
4
Treatments
3
Subtypes
1
Deep Research
◆

Subtypes

3
Seasonal Influenza
Annual epidemics caused by circulating influenza A and B strains undergoing antigenic drift.
Show evidence (1 reference)
PMID:29955068 SUPPORT Human Clinical
"Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift."
Describes the annual reformulation needed due to antigenic drift driving seasonal epidemics.
Pandemic Influenza
Global outbreaks caused by novel influenza A subtypes to which the population has little or no pre-existing immunity, arising from antigenic shift.
Show evidence (1 reference)
PMID:29955068 SUPPORT Human Clinical
"The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide."
Documents pandemic influenza and its catastrophic potential.
Avian Influenza
Influenza caused by avian-origin influenza A viruses (e.g., H5N1, H7N9) that can occasionally infect humans with high case fatality rates.
⚙

Pathophysiology

5
Respiratory Epithelial Infection and Cytopathic Effect
Influenza viruses bind to sialic acid residues on respiratory epithelial cells via hemagglutinin, followed by endocytosis and viral replication in the nucleus. Viral neuraminidase facilitates release of new virions. This causes direct cytopathic damage to airway epithelium, leading to desquamation, impaired mucociliary clearance, and susceptibility to secondary bacterial infection.
respiratory epithelial cell link alveolar macrophage link
viral genome replication link defense response to virus link
lung link respiratory system link
Show evidence (1 reference)
DOI:10.3390/pathogens13070561 SUPPORT Human Clinical
"Influenza virus possesses an RNA genome of single-stranded, negative-sensed, and segmented configuration. Influenza virus causes an acute respiratory disease, commonly known as the "flu" in humans. In some individuals, flu can lead to pneumonia and acute respiratory distress syndrome."
Describes influenza as an acute respiratory disease caused by viral infection of the respiratory tract.
Toll-like Receptor Signaling and Innate Immune Activation
Innate immune sensing of influenza occurs through endosomal TLR3, TLR7, and TLR8. TLR7/8 signal via MYD88 to activate IRF5/IRF7 and NF-kappaB, while TLR3 signals via TRIF to activate IRF3 via TBK1/IKK-epsilon. This dual signaling induces type I and III interferons, pro-inflammatory cytokines, and chemokines. The TLR response is a double-edged sword: necessary for viral control but capable of driving immunopathology when hyperactivated.
dendritic cell link macrophage link neutrophil link
toll-like receptor signaling pathway link response to type I interferon link
Show evidence (2 references)
DOI:10.3390/ijms25115909 SUPPORT In Vitro
"Because TLRs may act as a double-edged sword, a balanced TLR response is critical for the overall benefit of the host."
Confirms the dual role of TLR signaling in both antiviral defense and immunopathology during influenza.
DOI:10.3390/pathogens13070561 SUPPORT In Vitro
"Host cells sense IAV infection through multiple receptors and mechanisms, which culminate in the induction of a concerted innate antiviral response and the creation of an antiviral state, which inhibits and clears the infection from host cells."
Describes innate antiviral sensing mechanisms including TLR pathways.
Inflammasome Activation and Cytokine Storm
IAV infection activates NLRP3 and AIM2 inflammasomes. AIM2, canonically a cytosolic dsDNA sensor, is activated by host mitochondrial DNA released after IAV-induced mitochondrial damage. Inflammasome activation leads to caspase-1-mediated processing of IL-1-beta and IL-18, and gasdermin D-mediated pyroptosis. Excessive inflammasome activation contributes to the cytokine storm associated with severe influenza.
macrophage link
pyroptotic inflammatory response link
Show evidence (2 references)
DOI:10.3390/v16101535 SUPPORT Model Organism
"Paradoxically, AIM2 deficiency has been linked to both enhanced and reduced vulnerability to IAV infection."
Describes the complex role of AIM2 inflammasome in influenza pathogenesis.
DOI:10.3390/v16101535 SUPPORT Model Organism
"While a strong response is necessary for early viral control, overactivation of inflammasomes can precipitate harmful hyperinflammatory responses, a defining characteristic observed during severe influenza infections."
Confirms that inflammasome overactivation drives hyperinflammation in severe influenza.
PANoptosis and Inflammatory Cell Death
Influenza A virus triggers multiple regulated cell death pathways including apoptosis, necroptosis, and pyroptosis, integrated as PANoptosis. ZBP1 senses viral Z-RNA and coordinates these death pathways via RHIM-dependent interactions with RIPK3/RIPK1. MLKL-driven membrane rupture during necroptosis activates NLRP3 inflammasome. Caspase-3 can cleave gasdermin E, linking apoptosis to pyroptosis. This integrated cell death ensures viral clearance but can intensify tissue damage.
necroptotic process link programmed necrotic cell death link
Show evidence (1 reference)
DOI:10.3390/vetsci11110555 SUPPORT Model Organism
"Influenza A virus (IAV) infection initiates a complex interplay of cell death modalities, including apoptosis, necroptosis, pyroptosis, and their integration, known as PANoptosis, which significantly impacts host immune responses and tissue integrity."
Directly describes PANoptosis as integrated cell death modalities in IAV infection.
Endothelial Dysfunction and Thromboinflammation
Severe influenza involves pulmonary microvascular endothelial infection and activation, leading to vascular leakage, adhesion molecule upregulation (ICAM-1, VCAM-1), and thromboinflammatory complications including venous thromboembolism. In critically ill influenza cohorts, VTE incidence has been reported at 9.37%.
Show evidence (1 reference)
DOI:10.1177/10760296241278615 SUPPORT Human Clinical
"A total of 854 patients with severe influenza were included in the analysis. The incidence of VTE was 9.37% (80/854)."
Quantifies VTE incidence in critically ill influenza patients.
●

Phenotypes

10
Immune 1
Pneumonia OCCASIONAL Pneumonia (HP:0002090)
Show evidence (1 reference)
DOI:10.3390/pathogens13070561 SUPPORT Human Clinical
"In some individuals, flu can lead to pneumonia and acute respiratory distress syndrome."
Confirms pneumonia as a serious complication of influenza.
Metabolism 1
Fever VERY_FREQUENT Fever (HP:0001945)
Fever is a universally recognized cardinal symptom of influenza infection.
Nervous System 1
Headache FREQUENT Headache (HP:0002315)
Respiratory 4
Cough VERY_FREQUENT Cough (HP:0012735)
Sore Throat FREQUENT Pharyngitis (HP:0025439)
Rhinorrhea FREQUENT Rhinorrhea (HP:0031417)
Dyspnea OCCASIONAL Dyspnea (HP:0002094)
Constitutional 3
Myalgia FREQUENT Myalgia (HP:0003326)
Fatigue VERY_FREQUENT Fatigue (HP:0012378)
Chills FREQUENT Chills (HP:0025143)
💊

Treatments

4
Neuraminidase Inhibitors
Action: neuraminidase inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986
Oseltamivir (oral) and zanamivir (inhaled) inhibit viral neuraminidase, preventing release of new virions from infected cells. Most effective when administered within 48 hours of symptom onset.
Show evidence (1 reference)
PMID:29955068 SUPPORT Human Clinical
"Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy."
Confirms neuraminidase inhibitors as established influenza antivirals.
Cap-Dependent Endonuclease Inhibitor (Baloxavir Marboxil)
Action: baloxavir marboxil therapy Ontology label: Pharmacotherapy NCIT:C15986
Baloxavir marboxil inhibits the cap-dependent endonuclease of the influenza polymerase complex, blocking viral mRNA synthesis. Single-dose oral therapy that has shown faster symptom resolution compared to oseltamivir in real-world studies.
Annual Vaccination
Action: influenza vaccination Ontology label: vaccination MAXO:0001017
Seasonal influenza vaccination with inactivated, live-attenuated, recombinant, or cell-based vaccines targeting predicted circulating strains is the primary preventive measure.
Show evidence (1 reference)
PMID:29955068 SUPPORT Human Clinical
"Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift."
Describes the rationale for annual influenza vaccination.
Supportive Care
Action: supportive care MAXO:0000950
Antipyretics, hydration, and rest for mild cases. Mechanical ventilation and intensive care for severe respiratory failure.
{ }

Source YAML

click to show 
name: Influenza
creation_date: "2026-03-06T12:00:00Z"
updated_date: "2026-03-06T06:20:00Z"
description: >
  Influenza is an acute respiratory infectious disease caused by influenza viruses
  (types A and B in humans), transmitted via respiratory droplets. Influenza A
  and B cause seasonal epidemics, while influenza A is responsible for pandemics due to
  antigenic shift. The WHO estimates annual epidemics result in approximately 1 billion
  infections, 3-5 million cases of severe illness, and 300,000-500,000 deaths globally.
  The disease ranges from mild upper respiratory illness to severe pneumonia, acute
  respiratory distress syndrome, and death, particularly in elderly, immunocompromised,
  and young populations.
category: Infectious Disease
parents:
  - Viral Respiratory Infection
notes: >
  Influenza epidemiology: The WHO estimates annual epidemics result in approximately
  1 billion infections, 3-5 million cases of severe illness, and 300,000-500,000
  deaths globally. The 1918 pandemic resulted in over 40 million deaths worldwide.
  A core 6-gene ISG signature (IFI6, IFI44L, IRF7, ISG15, MX1, MX2) has been
  identified in human lung tissue as an early transcriptomic hallmark of influenza
  infection. Baloxavir resistance surveillance shows low but detectable prevalence of
  PA resistance markers (0.1% in IAV).
disease_term:
  preferred_term: influenza
  term:
    id: MONDO:0005812
    label: influenza
infectious_agent:
  - name: Influenza A virus
    infectious_agent_term:
      preferred_term: Influenza A virus
      term:
        id: NCBITaxon:11320
        label: Influenza A virus
    description: >
      Influenza A viruses are the most clinically significant type, capable of infecting
      humans, birds, pigs, and other animals. They are classified by hemagglutinin (H) and
      neuraminidase (N) surface glycoproteins and are responsible for seasonal epidemics
      and pandemics due to antigenic drift and shift.
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin."
        explanation: Confirms influenza A causes seasonal epidemics and pandemic outbreaks of zoonotic origin.
        evidence_source: HUMAN_CLINICAL
  - name: Influenza B virus
    infectious_agent_term:
      preferred_term: Influenza B virus
      term:
        id: NCBITaxon:11520
        label: Influenza B virus
    description: >
      Influenza B viruses primarily infect humans and cause seasonal epidemics. They undergo
      antigenic drift but not antigenic shift. The Yamagata lineage has not been detected
      globally since March 2020 and is considered functionally extinct; current vaccines
      have transitioned to trivalent formulations containing only the Victoria lineage.
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses."
        explanation: Confirms influenza B as a causative agent of human influenza.
        evidence_source: HUMAN_CLINICAL
has_subtypes:
  - name: Seasonal Influenza
    description: Annual epidemics caused by circulating influenza A and B strains undergoing antigenic drift.
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift."
        explanation: Describes the annual reformulation needed due to antigenic drift driving seasonal epidemics.
        evidence_source: HUMAN_CLINICAL
  - name: Pandemic Influenza
    description: >
      Global outbreaks caused by novel influenza A subtypes to which the population has
      little or no pre-existing immunity, arising from antigenic shift.
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "The most severe influenza pandemic, in 1918, resulted in >40 million deaths worldwide."
        explanation: Documents pandemic influenza and its catastrophic potential.
        evidence_source: HUMAN_CLINICAL
  - name: Avian Influenza
    description: >
      Influenza caused by avian-origin influenza A viruses (e.g., H5N1, H7N9) that
      can occasionally infect humans with high case fatality rates.
pathophysiology:
  - name: Respiratory Epithelial Infection and Cytopathic Effect
    description: >
      Influenza viruses bind to sialic acid residues on respiratory epithelial cells
      via hemagglutinin, followed by endocytosis and viral replication in the nucleus.
      Viral neuraminidase facilitates release of new virions. This causes direct cytopathic
      damage to airway epithelium, leading to desquamation, impaired mucociliary
      clearance, and susceptibility to secondary bacterial infection.
    cell_types:
      - preferred_term: respiratory epithelial cell
        term:
          id: CL:0002632
          label: epithelial cell of lower respiratory tract
      - preferred_term: alveolar macrophage
        term:
          id: CL:0000583
          label: alveolar macrophage
    biological_processes:
      - preferred_term: viral genome replication
        term:
          id: GO:0019079
          label: viral genome replication
      - preferred_term: defense response to virus
        term:
          id: GO:0051607
          label: defense response to virus
    locations:
      - preferred_term: lung
        term:
          id: UBERON:0002048
          label: lung
      - preferred_term: respiratory system
        term:
          id: UBERON:0001004
          label: respiratory system
    evidence:
      - reference: DOI:10.3390/pathogens13070561
        supports: SUPPORT
        snippet: "Influenza virus possesses an RNA genome of single-stranded, negative-sensed, and segmented configuration. Influenza virus causes an acute respiratory disease, commonly known as the \"flu\" in humans. In some individuals, flu can lead to pneumonia and acute respiratory distress syndrome."
        explanation: Describes influenza as an acute respiratory disease caused by viral infection of the respiratory tract.
        evidence_source: HUMAN_CLINICAL
  - name: Toll-like Receptor Signaling and Innate Immune Activation
    description: >
      Innate immune sensing of influenza occurs through endosomal TLR3, TLR7, and TLR8.
      TLR7/8 signal via MYD88 to activate IRF5/IRF7 and NF-kappaB, while TLR3 signals via
      TRIF to activate IRF3 via TBK1/IKK-epsilon. This dual signaling induces type I and III
      interferons, pro-inflammatory cytokines, and chemokines. The TLR response is a
      double-edged sword: necessary for viral control but capable of driving immunopathology
      when hyperactivated.
    cell_types:
      - preferred_term: dendritic cell
        term:
          id: CL:0000451
          label: dendritic cell
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
      - preferred_term: neutrophil
        term:
          id: CL:0000775
          label: neutrophil
    biological_processes:
      - preferred_term: toll-like receptor signaling pathway
        term:
          id: GO:0002224
          label: toll-like receptor signaling pathway
      - preferred_term: response to type I interferon
        term:
          id: GO:0034340
          label: response to type I interferon
    evidence:
      - reference: DOI:10.3390/ijms25115909
        supports: SUPPORT
        snippet: "Because TLRs may act as a double-edged sword, a balanced TLR response is critical for the overall benefit of the host."
        explanation: Confirms the dual role of TLR signaling in both antiviral defense and immunopathology during influenza.
        evidence_source: IN_VITRO
      - reference: DOI:10.3390/pathogens13070561
        supports: SUPPORT
        snippet: "Host cells sense IAV infection through multiple receptors and mechanisms, which culminate in the induction of a concerted innate antiviral response and the creation of an antiviral state, which inhibits and clears the infection from host cells."
        explanation: Describes innate antiviral sensing mechanisms including TLR pathways.
        evidence_source: IN_VITRO
  - name: Inflammasome Activation and Cytokine Storm
    description: >
      IAV infection activates NLRP3 and AIM2 inflammasomes. AIM2, canonically a cytosolic
      dsDNA sensor, is activated by host mitochondrial DNA released after IAV-induced
      mitochondrial damage. Inflammasome activation leads to caspase-1-mediated processing
      of IL-1-beta and IL-18, and gasdermin D-mediated pyroptosis. Excessive inflammasome
      activation contributes to the cytokine storm associated with severe influenza.
    cell_types:
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
    biological_processes:
      - preferred_term: pyroptotic inflammatory response
        term:
          id: GO:0070269
          label: pyroptotic inflammatory response
    evidence:
      - reference: DOI:10.3390/v16101535
        supports: SUPPORT
        snippet: "Paradoxically, AIM2 deficiency has been linked to both enhanced and reduced vulnerability to IAV infection."
        explanation: Describes the complex role of AIM2 inflammasome in influenza pathogenesis.
        evidence_source: MODEL_ORGANISM
      - reference: DOI:10.3390/v16101535
        supports: SUPPORT
        snippet: "While a strong response is necessary for early viral control, overactivation of inflammasomes can precipitate harmful hyperinflammatory responses, a defining characteristic observed during severe influenza infections."
        explanation: Confirms that inflammasome overactivation drives hyperinflammation in severe influenza.
        evidence_source: MODEL_ORGANISM
  - name: PANoptosis and Inflammatory Cell Death
    description: >
      Influenza A virus triggers multiple regulated cell death pathways including apoptosis,
      necroptosis, and pyroptosis, integrated as PANoptosis. ZBP1 senses viral Z-RNA and
      coordinates these death pathways via RHIM-dependent interactions with RIPK3/RIPK1.
      MLKL-driven membrane rupture during necroptosis activates NLRP3 inflammasome.
      Caspase-3 can cleave gasdermin E, linking apoptosis to pyroptosis. This integrated
      cell death ensures viral clearance but can intensify tissue damage.
    biological_processes:
      - preferred_term: necroptotic process
        term:
          id: GO:0070266
          label: necroptotic process
      - preferred_term: programmed necrotic cell death
        term:
          id: GO:0097300
          label: programmed necrotic cell death
    evidence:
      - reference: DOI:10.3390/vetsci11110555
        supports: SUPPORT
        snippet: "Influenza A virus (IAV) infection initiates a complex interplay of cell death modalities, including apoptosis, necroptosis, pyroptosis, and their integration, known as PANoptosis, which significantly impacts host immune responses and tissue integrity."
        explanation: Directly describes PANoptosis as integrated cell death modalities in IAV infection.
        evidence_source: MODEL_ORGANISM
  - name: Endothelial Dysfunction and Thromboinflammation
    description: >
      Severe influenza involves pulmonary microvascular endothelial infection and activation,
      leading to vascular leakage, adhesion molecule upregulation (ICAM-1, VCAM-1),
      and thromboinflammatory complications including venous thromboembolism. In critically
      ill influenza cohorts, VTE incidence has been reported at 9.37%.
    evidence:
      - reference: DOI:10.1177/10760296241278615
        supports: SUPPORT
        snippet: "A total of 854 patients with severe influenza were included in the analysis. The incidence of VTE was 9.37% (80/854)."
        explanation: Quantifies VTE incidence in critically ill influenza patients.
        evidence_source: HUMAN_CLINICAL
phenotypes:
  - category: Constitutional
    name: Fever
    description: Acute onset of high fever (38-41 degrees C) is a hallmark of influenza.
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Fever
      term:
        id: HP:0001945
        label: Fever
    notes: Fever is a universally recognized cardinal symptom of influenza infection.
  - category: Respiratory
    name: Cough
    description: Dry or productive cough is one of the most common symptoms of influenza.
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Cough
      term:
        id: HP:0012735
        label: Cough
  - category: Constitutional
    name: Myalgia
    description: Diffuse muscle aches are characteristic of influenza infection.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Myalgia
      term:
        id: HP:0003326
        label: Myalgia
  - category: Constitutional
    name: Headache
    description: Frontal or generalized headache accompanies acute influenza.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Headache
      term:
        id: HP:0002315
        label: Headache
  - category: Respiratory
    name: Sore Throat
    description: Pharyngitis occurs frequently with influenza infection.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Sore throat
      term:
        id: HP:0025439
        label: Pharyngitis
  - category: Constitutional
    name: Fatigue
    description: Profound fatigue and malaise may persist for weeks after acute illness.
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Fatigue
      term:
        id: HP:0012378
        label: Fatigue
  - category: Constitutional
    name: Chills
    description: Rigors and chills frequently accompany the febrile phase.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Chills
      term:
        id: HP:0025143
        label: Chills
  - category: Respiratory
    name: Rhinorrhea
    description: Nasal congestion and rhinorrhea are common upper respiratory symptoms.
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Rhinorrhea
      term:
        id: HP:0031417
        label: Rhinorrhea
  - category: Respiratory
    name: Dyspnea
    description: Shortness of breath occurs in severe cases, particularly with viral pneumonia.
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Dyspnea
      term:
        id: HP:0002094
        label: Dyspnea
  - category: Respiratory
    name: Pneumonia
    description: >
      Primary viral pneumonia or secondary bacterial pneumonia is the most serious
      pulmonary complication and a leading cause of influenza-related mortality.
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Pneumonia
      term:
        id: HP:0002090
        label: Pneumonia
    evidence:
      - reference: DOI:10.3390/pathogens13070561
        supports: SUPPORT
        snippet: "In some individuals, flu can lead to pneumonia and acute respiratory distress syndrome."
        explanation: Confirms pneumonia as a serious complication of influenza.
        evidence_source: HUMAN_CLINICAL
treatments:
  - name: Neuraminidase Inhibitors
    description: >
      Oseltamivir (oral) and zanamivir (inhaled) inhibit viral neuraminidase,
      preventing release of new virions from infected cells. Most effective when
      administered within 48 hours of symptom onset.
    treatment_term:
      preferred_term: neuraminidase inhibitor therapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy."
        explanation: Confirms neuraminidase inhibitors as established influenza antivirals.
        evidence_source: HUMAN_CLINICAL
  - name: Cap-Dependent Endonuclease Inhibitor (Baloxavir Marboxil)
    description: >
      Baloxavir marboxil inhibits the cap-dependent endonuclease of the influenza
      polymerase complex, blocking viral mRNA synthesis. Single-dose oral therapy
      that has shown faster symptom resolution compared to oseltamivir in real-world studies.
    treatment_term:
      preferred_term: baloxavir marboxil therapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
  - name: Annual Vaccination
    description: >
      Seasonal influenza vaccination with inactivated, live-attenuated, recombinant,
      or cell-based vaccines targeting predicted circulating strains is the primary
      preventive measure.
    treatment_term:
      preferred_term: influenza vaccination
      term:
        id: MAXO:0001017
        label: vaccination
    evidence:
      - reference: PMID:29955068
        reference_title: "Influenza."
        supports: SUPPORT
        snippet: "Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift."
        explanation: Describes the rationale for annual influenza vaccination.
        evidence_source: HUMAN_CLINICAL
  - name: Supportive Care
    description: >
      Antipyretics, hydration, and rest for mild cases. Mechanical ventilation and
      intensive care for severe respiratory failure.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 52 citations 2026-03-06T03:54:22.131615

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Influenza
  • MONDO ID: (if available)
  • Category: Infectious Disease

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Influenza. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Influenza pathophysiology (molecular & cellular mechanisms) — research report (2023–2024 emphasis)

Disease & scope

Disease: Influenza (primarily influenza A virus (IAV), but mechanisms generalize to influenza B in many host-response pathways).
Category: Infectious disease (acute respiratory viral infection).
MONDO ID: Not retrieved in current tool context.

Executive summary

Influenza pathophysiology reflects the coupled dynamics of (i) viral infection/replication in respiratory epithelial cells, (ii) host innate recognition (notably TLR3/7/8 and other PRRs) that drives interferon and inflammatory programs, (iii) inflammasome-driven IL‑1 family cytokine release and inflammatory cell death (pyroptosis/necroptosis/PANoptosis), and (iv) downstream tissue injury including endothelial barrier dysfunction, vascular leakage, and thromboinflammatory complications in severe disease. Recent 2023–2024 human and translational studies sharpen this model by defining cell-type-resolved early lung signatures (e.g., a core 6-gene interferon/ISG module) and by quantifying real-world treatment effects (baloxavir vs oseltamivir) and severe-complication rates (e.g., thrombosis incidence in critically ill cohorts). (an2024hostinnateantiviral pages 1-2, an2024hostinnateantiviral pages 4-5, sohail2024differentialtranscriptomichost pages 10-12, qiu2024thrombosisincritically pages 1-2)

Mechanism / Stage Key Molecules (HGNC/Viral) Key Pathways / GO Processes Key Cellular Components (GO CC) Key Cell Types (CL) Anatomical Sites (UBERON) Representative Evidence (2023–2024) Source IDs
Viral Entry & Replication Viral: HA, NA, M2, NP, PA, PB1, PB2; Host: Sialic acid receptors Viral entry via endocytosis; Viral genome replication; Viral transcription Endosome; Nucleus; Plasma membrane Airway epithelial cell (CL:0000066); Macrophage (CL:0000235) Respiratory tract; Lung An et al. 2024 (Review): Summarizes viral cycle and 17+ viral proteins modulating host response. (an2024hostinnateantiviral pages 1-2)
Innate Sensing (TLRs) TLR3, TLR7, TLR8, TLR4, TLR10; Adaptors: MYD88, TICAM1 (TRIF); TFs: IRF3, IRF7, NFKB1 Toll-like receptor signaling pathway; MyD88-dependent/independent signaling; Cytokine production Endosome membrane; Cell surface Dendritic cell; Macrophage; Neutrophil Lung Kayesh et al. 2024 (Review): TLR3/7/9 play key antiviral roles; TLR4 senses DAMPs; TLR agonists as adjuvants. (kayesh2024recentinsightsinto pages 4-5, kayesh2024recentinsightsinto pages 2-4, kayesh2024recentinsightsinto pages 1-2)
Core Interferon & ISG Response IFI6, IFI44L, IRF7, ISG15, MX1, MX2, CCL8 Response to type I interferon; Defense response to virus; Cytokine-mediated signaling Cytoplasm; Nucleus Airway epithelial cell (predominant infection); Macrophage Lung parenchyma; Bronchus Sohail et al. 2024 (Primary, Human Lung Explant): Identified 6-gene core ISG signature (IFI6, IFI44L, IRF7, ISG15, MX1, MX2) in early infection. (sohail2024differentialtranscriptomichost pages 10-12, sohail2024differentialtranscriptomichost pages 1-2)
Inflammasome Activation NLRP3, AIM2, PYCARD (ASC), CASP1, IL1B, IL18, GSDMD Inflammasome complex assembly; Pyroptosis; Interleukin-1 beta production Inflammasome complex; Cytosol Macrophage; Monocyte Lung; Respiratory mucosa Xu & Tate 2024 (Review): AIM2 senses IAV-induced host DNA damage (mtDNA/NETs); drives IL-1β/IL-18 release. (xu2024takingaimat pages 7-9, kayesh2024recentinsightsinto pages 1-2)
Cell Death (PANoptosis) ZBP1 (sensor), RIPK1, RIPK3, MLKL, CASP8, CASP3, GSDMD, GSDME PANoptosis; Necroptosis; Apoptosis; Pyroptosis Cytosol; Plasma membrane (pore complex) Infected epithelial cell; Macrophage Lung epithelium Sun & Liu 2024 (Review): IAV triggers ZBP1-dependent PANoptosis; crosstalk between death pathways drives immunopathology. (sun2024mechanisticinsightsinto pages 10-11, sun2024mechanisticinsightsinto pages 11-13, an2024hostinnateantiviral pages 1-2)
Endothelial Dysfunction & Thrombosis VWF, SELE (P-selectin), F3 (Tissue Factor), IL6, IL1B Blood coagulation; Platelet activation; Endothelial cell activation; Glycocalyx degradation Endothelial glycocalyx; Blood microvessel Pulmonary microvascular endothelial cell; Platelet Lung vasculature; Systemic vessels Qiu et al. 2024 (Prospective Cohort): 9.37% VTE incidence in severe flu; aspirin associated with reduced risk (aOR 0.37). (qiu2024thrombosisincritically pages 2-3, qiu2024thrombosisincritically pages 1-2)
Mucosal Vaccination Response IL33 (alarmin), IFNG, CXCL10, OASL, DDX58 Mucosal immune response; Compartmentalized antibody production (IgA) Extracellular space (mucosa); Nasal epithelium Nasal epithelial cell; CD8+ T cell; cTfh cell Nasal mucosa Thwaites et al. 2023 (Primary, Human Challenge): Early nasal IL-33 (<8h) correlates with distinct mucosal antibody response. (thwaites2023earlymucosalevents pages 9-10, thwaites2023earlymucosalevents pages 2-2, thwaites2023earlymucosalevents pages 1-2)
Real-world Antiviral Therapy Baloxavir marboxil (target: PA); Oseltamivir (target: NA) Viral RNA transcription inhibition; Viral release inhibition Nucleus (PA target); Virion surface (NA target) Infected host cells Respiratory tract Cai et al. 2024 (Real-world Cohort): Baloxavir reduced symptom duration (median 28h vs 48h; aHR 1.35) vs Oseltamivir. (cai2024realworldeffectivenessand pages 1-2, cai2024realworldeffectivenessand media 252c64e8)

Table: A structured summary of key influenza pathophysiological mechanisms, molecular players, affected cells/tissues, and recent clinical findings extracted from 2023–2024 literature.

1) Core pathophysiology: key concepts and definitions (current understanding)

1.1 Viral tropism and replication

IAV is an enveloped, segmented negative-sense ssRNA virus whose genome is packaged as eight vRNPs with NP and polymerase subunits PA/PB1/PB2; the virion surface contains HA, NA, and M2. HA binds sialic-acid receptors, enabling endocytic entry; vRNPs traffic to the nucleus for transcription/replication; progeny virions bud from the plasma membrane. (an2024hostinnateantiviral pages 1-2)

Mechanistic implication: the need for nuclear replication and the requirement for HA/NA/M2 at distinct lifecycle stages creates multiple intervention points (PA cap-dependent endonuclease inhibition; NA inhibition; host-directed blockade of entry/trafficking). (an2024hostinnateantiviral pages 1-2)

1.2 Innate sensing as a “double-edged sword”

A central concept in modern influenza pathophysiology is that early innate sensing is necessary for viral control but can also drive immunopathology. The innate response can become “hyperactive” and damage host tissues if not properly regulated. (an2024hostinnateantiviral pages 1-2)

2) Primary molecular pathways dysregulated in influenza

2.1 TLR-driven sensing → IRF/NF‑κB programs

Recent 2024 reviews consolidate evidence that endosomal TLRs are major influenza sensors and define canonical signaling routes.

Key mechanistic statement (signal flow): * TLR7/TLR8 signal via MYD88 to activate IRF5/IRF7, AP‑1, and NF‑κB. * TLR3 signals via TRIF (TICAM1) to activate IRF3 (via TBK1/IKKε) and NF‑κB-associated programs. * The consequence is transcription of interferons, cytokines, and pro-inflammatory mediators. (an2024hostinnateantiviral pages 4-5)

Definitions/notes: Kayesh et al. (2024) emphasize that multiple TLRs participate (TLR2/3/4/7/8/9/10) and that TLRs can be “a double-edged sword,” motivating interest in balanced modulation and use of TLR agonists as adjuvants. (kayesh2024recentinsightsinto pages 2-4, kayesh2024recentinsightsinto pages 8-10)

2.2 Interferon and ISG responses as early tissue-scale signatures

A key 2024 human lung explant study (bulk + scRNA-seq) provides direct evidence of early (first 24h) lung antiviral transcriptional programs.

Predominant infected cell types: airway epithelial cells and macrophages. (sohail2024differentialtranscriptomichost pages 1-2)

Core ISG module (6 mRNAs): IFI6, IFI44L, IRF7, ISG15, MX1, MX2. (sohail2024differentialtranscriptomichost pages 1-2)

Additional inflammatory/chemokine signal: infection induced “brisk interferon responses,” with CCL8 described as the most strongly upregulated mRNA. (sohail2024differentialtranscriptomichost pages 1-2)

Pathway-level dysregulation: Gene set enrichment showed induction of IFNα/IFNγ response programs, IL6–JAK–STAT3 signaling, and TNFα signaling via NF‑κB, with suppression of cell-cycle programs (E2F targets). (sohail2024differentialtranscriptomichost pages 8-10)

2.3 Inflammasomes and IL‑1 family cytokines

Inflammasome signaling is increasingly framed as central to severe influenza immunopathology, linking PRR activation, cell death, and IL‑1 family cytokines.

AIM2 inflammasome in influenza

A major 2024 review focuses on AIM2 (Absent in Melanoma 2), canonically a cytosolic dsDNA sensor, but “unexpectedly” implicated in IAV (an RNA virus). (xu2024takingaimat pages 2-4)

Mechanism: IAV-associated host DNA (especially mitochondrial DNA released after mitochondrial damage; also DNA from NETs or phagocytosed material) can activate AIM2, recruiting ASC and caspase-1, leading to IL‑1β/IL‑18 processing and gasdermin-mediated pyroptosis. (xu2024takingaimat pages 7-9, xu2024takingaimat pages 2-4)

Clinical/pathology linkage: excessive IL‑1β/IL‑18 correlates with severity in multiple influenza subtypes; and gasdermin D deficiency is cited as protective in mouse influenza hyperinflammation/lung damage contexts. (xu2024takingaimat pages 2-4)

Important nuance (expert synthesis): AIM2’s role is context-dependent, with “AIM2 deficiency… linked to both enhanced and reduced vulnerability to IAV infection,” suggesting timing/strain/dose and redundancy with other sensors (e.g., cGAS-STING, NLRP3) influence phenotype. (xu2024takingaimat pages 1-2, xu2024takingaimat pages 5-7)

2.4 Programmed cell death and PANoptosis (tissue injury vs viral control)

A 2024 mechanistic review synthesizes how influenza engages apoptosis, necroptosis, pyroptosis, and integrated PANoptosis.

Key sensor: ZBP1 recognizes viral Z-RNA and coordinates apoptosis/necroptosis/pyroptosis via RHIM-dependent interactions with RIPK3/RIPK1. (sun2024mechanisticinsightsinto pages 4-6, sun2024mechanisticinsightsinto pages 6-8)

Necroptosis arm: RIPK1/RIPK3 → MLKL phosphorylation → MLKL oligomerization and pore formation; MLKL-driven membrane rupture can drive potassium efflux that activates NLRP3 inflammasome. (sun2024mechanisticinsightsinto pages 4-6, sun2024mechanisticinsightsinto pages 8-10)

Pyroptosis arm: Inflammasome-activated caspase-1 cleaves GSDMD; caspase-3 can cleave GSDME (linking apoptosis to pyroptosis). (sun2024mechanisticinsightsinto pages 8-10)

Integrated PANoptosis: PANoptosis can “ensure[] the efficient elimination of infected cells while triggering a robust inflammatory response,” illustrating the mechanistic tradeoff between clearance and immunopathology. (sun2024mechanisticinsightsinto pages 11-13)

3) Key molecular players (knowledge-base style)

3.1 Host genes/proteins (examples supported by 2024 sources)

Innate sensing & signaling: TLR3, TLR7, TLR8, MYD88, TICAM1/TRIF, IRF3, IRF7, NFKB1 (an2024hostinnateantiviral pages 4-5, kayesh2024recentinsightsinto pages 2-4)
ISG module / antiviral state: IFI6, IFI44L, IRF7, ISG15, MX1, MX2 (sohail2024differentialtranscriptomichost pages 1-2)
Inflammasome & cytokines: AIM2, NLRP3, PYCARD/ASC, CASP1, IL1B, IL18, GSDMD (xu2024takingaimat pages 2-4, sun2024mechanisticinsightsinto pages 10-11)
Cell death (PANoptosis): ZBP1, RIPK1, RIPK3, MLKL, CASP8, CASP3, GSDME (sun2024mechanisticinsightsinto pages 10-11, sun2024mechanisticinsightsinto pages 4-6)
Endothelial/thromboinflammation: VWF (von Willebrand factor), ICAM1, VCAM1; tissue factor pathway is discussed in thrombosis context (marchenko2024endothelialactivationand pages 12-13, qiu2024thrombosisincritically pages 1-2)

3.2 Viral proteins implicated

HA (entry), NA (release), M2 (ion channel; implicated in inflammasome/mitochondrial perturbation in reviews), polymerase components PA/PB1/PB2 and accessory proteins including NS1 (immune antagonism), PB1-F2 (mitochondrial damage; inflammasome-related context), PA-X (host shutoff context). (an2024hostinnateantiviral pages 1-2, xu2024takingaimat pages 7-9)

3.3 Chemical entities / drugs (real-world and translational)

  • Baloxavir marboxil (targets viral polymerase acidic (PA) cap-dependent endonuclease). (cai2024realworldeffectivenessand pages 1-2)
  • Oseltamivir (neuraminidase inhibitor targeting NA). (cai2024realworldeffectivenessand pages 1-2)

4) Key cell types and anatomical locations

4.1 Cell types (with evidence)

Airway epithelial cells and macrophages are identified as predominant IAV host cells early after infection in human lung tissue explants (24h). (sohail2024differentialtranscriptomichost pages 1-2)

Inflammatory responses can occur in bystander cell types with few/no detectable viral transcripts, indicating paracrine cytokine signaling and tissue-level propagation of innate programs. (sohail2024differentialtranscriptomichost pages 1-2)

4.2 Anatomical sites

  • Nasal mucosa / upper airway: critical for mucosal vaccination responses; LAIV provokes early IL‑33 and subsequent IFN-associated mucosal programs. (thwaites2023earlymucosalevents pages 1-2, thwaites2023earlymucosalevents pages 2-2)
  • Lower airway / lung parenchyma: key site of viral pneumonia, ISG responses, inflammatory cell recruitment, and cell death-mediated injury. (sohail2024differentialtranscriptomichost pages 1-2, sun2024mechanisticinsightsinto pages 11-13)
  • Pulmonary microvasculature / endothelium: endothelial infection/activation contributes to leakage and thromboinflammatory complications in severe disease. (marchenko2024endothelialactivationand pages 12-13)

5) Disease progression: sequence of events (stage model)

  1. Exposure & entry: HA binds sialic acid receptors; endocytosis and fusion release vRNPs. (an2024hostinnateantiviral pages 1-2)
  2. Early replication (hours–day 1): nuclear replication/transcription; early innate sensing begins. (an2024hostinnateantiviral pages 1-2)
  3. Innate immune amplification: TLR3/7/8 signaling activates IRFs and NF‑κB, inducing interferons/cytokines and ISGs. (an2024hostinnateantiviral pages 4-5)
  4. Tissue-scale antiviral state: core ISG module (IFI6/IFI44L/IRF7/ISG15/MX1/MX2) emerges as an early hallmark in human lung tissue, with chemokines such as CCL8 prominent. (sohail2024differentialtranscriptomichost pages 1-2)
  5. Inflammasome and inflammatory cell death: AIM2 and NLRP3 pathways process IL‑1β/IL‑18; ZBP1-coordinated PANoptosis links viral nucleic acid sensing to apoptosis/necroptosis/pyroptosis; the combined effect can clear infection but also intensify inflammation. (xu2024takingaimat pages 2-4, sun2024mechanisticinsightsinto pages 11-13)
  6. Barrier dysfunction and systemic complications in severe disease: endothelial activation/dysfunction promotes vascular leakage and supports thrombosis risk; critically ill cohorts show measurable VTE incidence. (marchenko2024endothelialactivationand pages 12-13, qiu2024thrombosisincritically pages 1-2)

6) Phenotypic manifestations (mechanism → phenotype links)

6.1 Respiratory phenotypes

  • Viral pneumonia / ARDS-like lung injury: driven by cytokine and inflammasome activation and inflammatory cell death; PANoptosis is explicitly linked to “robust inflammatory response” that can contribute to tissue damage. (sun2024mechanisticinsightsinto pages 11-13, xu2024takingaimat pages 1-2)

6.2 Thromboinflammatory phenotypes

A cohort of 854 adults with severe influenza reported VTE incidence 9.37% (80/854); thrombosis was associated with greater requirement for advanced respiratory support (mechanical ventilation, ECMO) and higher co-infection incidence. (qiu2024thrombosisincritically pages 1-2)

Mechanistically, reviews link influenza to endothelial activation and dysfunction, including pulmonary microvascular endothelial infection, leakage, cytokine release, adhesion molecule upregulation (ICAM‑1/VCAM‑1), and NET-associated damage. (marchenko2024endothelialactivationand pages 12-13)

7) Recent developments and real-world implementations (2023–2024)

7.1 Real-world antiviral effectiveness: baloxavir vs oseltamivir

A multicenter real-world ambispective cohort study in outpatient fever clinics in East China (study period 2022.06–2023.06; published 23 July 2024, DOI: https://doi.org/10.3389/fmicb.2024.1428095) enrolled 509 influenza A outpatients.

Key findings: * Median time to alleviation of all influenza symptoms (TTAIS): 28.0 h (baloxavir) vs 48.0 h (oseltamivir). (cai2024realworldeffectivenessand pages 1-2) * Median time to alleviation of fever (TTAF): 18 h vs 30 h. (cai2024realworldeffectivenessand pages 1-2) * Multivariable Cox model: baloxavir associated with faster symptom alleviation (HR ~1.36) and fever resolution (HR ~1.93) compared to oseltamivir. (cai2024realworldeffectivenessand pages 1-2)

The main Kaplan–Meier and adjusted hazard ratio results are visualized in the extracted Figure/Table crops. (cai2024realworldeffectivenessand media 252c64e8, cai2024realworldeffectivenessand media b5b8ace7)

7.2 Antiviral resistance surveillance: baloxavir PA substitutions

A 2024 surveillance analysis of PA sequences in the Americas (published Sep 2024; DOI: https://doi.org/10.2147/DHPS.S470868) analyzed 58,816 IAV and 14,684 IBV PA sequences (up to May 31, 2023).

Key statistics: * IAV: 55/58,816 (0.1%) with resistance markers (~1 in 1000). (acocaljuarez2024baloxavirresistancemarkers pages 2-4) * Most frequent IAV markers: I38V (21), I38M (7), E199G (9). (acocaljuarez2024baloxavirresistancemarkers pages 2-4) * IBV: 8/14,684 (0.05%) with markers; M34I (5) and I38V (3). (acocaljuarez2024baloxavirresistancemarkers pages 4-7)

Clinical relevance emphasized: I38M is described as causing about a tenfold reduction in susceptibility, motivating ongoing molecular surveillance (with noted geographic sequencing gaps). (acocaljuarez2024baloxavirresistancemarkers pages 4-7, acocaljuarez2024baloxavirresistancemarkers pages 7-9)

7.3 Vaccine technology trends and mucosal vaccination rationale

A 2024 Clinical Microbiology Reviews overview emphasizes that limitations of current seasonal vaccines (e.g., egg adaptation, moderate effectiveness) motivate new technologies (cell-based, recombinant, adjuvanted/high-dose, LAIV, nucleic-acid vaccines including mRNA). (clark2024recentadvancesin pages 12-14, clark2024recentadvancesin pages 25-27)

The review notes that LAIV requires intranasal delivery and can elicit mucosal responses (including mucosal IgA), which may better prevent infection at the point of entry; it also summarizes effectiveness/effect size examples (e.g., LAIV reducing ILI by 31% in cited data; cell-based QIIV reducing lab-confirmed influenza by 54.6% in children). (clark2024recentadvancesin pages 19-22)

7.4 Mechanistic immunology of intranasal LAIV in humans (2023)

A Nature Communications 2023 study (Received 18 May 2023; Accepted 22 Nov 2023; DOI: https://doi.org/10.1038/s41467-023-43842-7) reports that LAIV induces “distinct, compartmentalized, antibody responses in the mucosa and blood,” and identifies early mucosal IL‑33 release within the first 8 hours as associated with these response patterns. The study is registered as NCT04110366. (thwaites2023earlymucosalevents pages 1-2)

8) GO/Cellular component and ontology-oriented curation snippets

Below are curation-ready suggestions (labels; IDs not computed here) aligned with evidence above:

8.1 GO Biological Process candidates (examples)

  • Toll-like receptor signaling pathway (TLR3/TLR7/TLR8; MYD88/TRIF) (an2024hostinnateantiviral pages 4-5, kayesh2024recentinsightsinto pages 2-4)
  • Response to type I interferon; interferon-stimulated gene expression (IFI6/IFI44L/IRF7/ISG15/MX1/MX2) (sohail2024differentialtranscriptomichost pages 1-2)
  • Cytokine-mediated signaling pathway; TNFα signaling via NF‑κB; IL6–JAK–STAT3 signaling (sohail2024differentialtranscriptomichost pages 8-10)
  • Inflammasome complex assembly; IL‑1β and IL‑18 production (AIM2/NLRP3/ASC/CASP1) (xu2024takingaimat pages 2-4, sun2024mechanisticinsightsinto pages 10-11)
  • Pyroptosis; necroptosis; apoptosis; PANoptosis (ZBP1/RIPK1/RIPK3/MLKL; caspases; gasdermins) (sun2024mechanisticinsightsinto pages 11-13, sun2024mechanisticinsightsinto pages 8-10)
  • Blood coagulation / immunothrombosis-like processes; endothelial activation (marchenko2024endothelialactivationand pages 12-13, qiu2024thrombosisincritically pages 1-2)

8.2 GO Cellular Component candidates

  • Endosome; nucleus (viral entry/nuclear replication) (an2024hostinnateantiviral pages 1-2)
  • Inflammasome complex; cytosol (AIM2/ASC/CASP1) (xu2024takingaimat pages 2-4)
  • Plasma membrane pore complex (MLKL, gasdermins) (sun2024mechanisticinsightsinto pages 4-6, sun2024mechanisticinsightsinto pages 8-10)
  • Endothelial glycocalyx / junctional complexes (barrier dysfunction context) (marchenko2024endothelialactivationand pages 12-13)

8.3 Phenotype (HP) candidates (labels)

  • Fever; cough; influenza-like illness; viral pneumonia; acute respiratory distress syndrome (ARDS) (inferred linkage to described mechanisms of lung injury and severe respiratory disease) (an2024hostinnateantiviral pages 1-2, xu2024takingaimat pages 1-2)
  • Venous thromboembolism (VTE) (qiu2024thrombosisincritically pages 1-2)

9) Evidence highlights (direct-quote style snippets)

  • TLR signaling architecture (MYD88 vs TRIF; IRF3/7/NF‑κB activation) is explicitly summarized in the Pathogens 2024 review excerpt describing Myddosome formation and TRIF→TRAF3→TBK1/IKKε→IRF3 phosphorylation. (an2024hostinnateantiviral pages 4-5)
  • Human lung early response: the Respiratory Research 2024 paper identifies a 6‑mRNA “core transcriptomic response” (IFI6, IFI44L, IRF7, ISG15, MX1, MX2) and states airway epithelial cells and macrophages are predominant host cells. (sohail2024differentialtranscriptomichost pages 1-2)
  • AIM2 paradox: “AIM2 deficiency has been linked to both enhanced and reduced vulnerability to IAV infection.” (xu2024takingaimat pages 1-2)
  • PANoptosis tradeoff: PANoptosis “ensures the efficient elimination of infected cells while triggering a robust inflammatory response.” (sun2024mechanisticinsightsinto pages 11-13)

10) Limitations of this tool-based synthesis (PMID requirement)

Several included sources are clearly peer-reviewed and provide DOIs and journal metadata. However, PMIDs/PMCIDs were not consistently extractable from the provided text snippets within this tool run (e.g., Qiu et al. and Cai et al. excerpts did not contain PubMed identifiers). Where PMIDs are required for curation, the DOIs provided should be used to resolve the PubMed records.

Key recent references (URLs; publication dates from retrieved text)

  • Cai et al. “Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir…” Published 23 Jul 2024. https://doi.org/10.3389/fmicb.2024.1428095 (cai2024realworldeffectivenessand pages 1-2)
  • Sohail et al. “Differential transcriptomic host responses…” 2024. https://doi.org/10.1186/s12931-024-02988-8 (sohail2024differentialtranscriptomichost pages 1-2)
  • Kayesh et al. “Recent Insights… TLR response…” Published 29 May 2024. https://doi.org/10.3390/ijms25115909 (kayesh2024recentinsightsinto pages 1-2)
  • An et al. “Host innate antiviral response…” Published 3 Jul 2024. https://doi.org/10.3390/pathogens13070561 (an2024hostinnateantiviral pages 1-2)
  • Xu & Tate. “Taking AIM at Influenza…” Sep 2024. https://doi.org/10.3390/v16101535 (xu2024takingaimat pages 1-2)
  • Sun & Liu. “Mechanistic insights into influenza A virus-induced cell death…” Nov 2024. https://doi.org/10.3390/vetsci11110555 (sun2024mechanisticinsightsinto pages 1-2)
  • Thwaites et al. “Early mucosal events…” 2023. https://doi.org/10.1038/s41467-023-43842-7 (thwaites2023earlymucosalevents pages 1-2)
  • Acocal-Juárez et al. “Baloxavir resistance markers…” Sep 2024. https://doi.org/10.2147/DHPS.S470868 (acocaljuarez2024baloxavirresistancemarkers pages 2-4)
  • Qiu et al. “Thrombosis in Critically Ill Influenza Patients…” 2024. https://doi.org/10.1177/10760296241278615 (qiu2024thrombosisincritically pages 1-2)

References

  1. (an2024hostinnateantiviral pages 1-2): Wenlong An, Simran Lakhina, Jessica Leong, Kartik Rawat, and Matloob Husain. Host innate antiviral response to influenza a virus infection: from viral sensing to antagonism and escape. Pathogens, 13:561, Jul 2024. URL: https://doi.org/10.3390/pathogens13070561, doi:10.3390/pathogens13070561. This article has 18 citations.

  2. (an2024hostinnateantiviral pages 4-5): Wenlong An, Simran Lakhina, Jessica Leong, Kartik Rawat, and Matloob Husain. Host innate antiviral response to influenza a virus infection: from viral sensing to antagonism and escape. Pathogens, 13:561, Jul 2024. URL: https://doi.org/10.3390/pathogens13070561, doi:10.3390/pathogens13070561. This article has 18 citations.

  3. (sohail2024differentialtranscriptomichost pages 10-12): Aaqib Sohail, Fakhar H. Waqas, Peter Braubach, Laurien Czichon, Mohamed Samir, Azeem Iqbal, Leonardo de Araujo, Stephan Pleschka, Michael Steinert, Robert Geffers, and Frank Pessler. Differential transcriptomic host responses in the early phase of viral and bacterial infections in human lung tissue explants ex vivo. Respiratory Research, Oct 2024. URL: https://doi.org/10.1186/s12931-024-02988-8, doi:10.1186/s12931-024-02988-8. This article has 9 citations and is from a domain leading peer-reviewed journal.

  4. (qiu2024thrombosisincritically pages 1-2): Xianming Qiu, Mingjie Liu, Quanzhen Wang, Yuke Zhang, Li Kong, and Lei Zhou. Thrombosis in critically ill influenza patients: incidence and risk factors. Clinical and Applied Thrombosis/Hemostasis, Jan 2024. URL: https://doi.org/10.1177/10760296241278615, doi:10.1177/10760296241278615. This article has 3 citations.

  5. (kayesh2024recentinsightsinto pages 4-5): Mohammad Enamul Hoque Kayesh, Michinori Kohara, and Kyoko Tsukiyama-Kohara. Recent insights into the molecular mechanisms of the toll-like receptor response to influenza virus infection. International Journal of Molecular Sciences, 25:5909, May 2024. URL: https://doi.org/10.3390/ijms25115909, doi:10.3390/ijms25115909. This article has 15 citations.

  6. (kayesh2024recentinsightsinto pages 2-4): Mohammad Enamul Hoque Kayesh, Michinori Kohara, and Kyoko Tsukiyama-Kohara. Recent insights into the molecular mechanisms of the toll-like receptor response to influenza virus infection. International Journal of Molecular Sciences, 25:5909, May 2024. URL: https://doi.org/10.3390/ijms25115909, doi:10.3390/ijms25115909. This article has 15 citations.

  7. (kayesh2024recentinsightsinto pages 1-2): Mohammad Enamul Hoque Kayesh, Michinori Kohara, and Kyoko Tsukiyama-Kohara. Recent insights into the molecular mechanisms of the toll-like receptor response to influenza virus infection. International Journal of Molecular Sciences, 25:5909, May 2024. URL: https://doi.org/10.3390/ijms25115909, doi:10.3390/ijms25115909. This article has 15 citations.

  8. (sohail2024differentialtranscriptomichost pages 1-2): Aaqib Sohail, Fakhar H. Waqas, Peter Braubach, Laurien Czichon, Mohamed Samir, Azeem Iqbal, Leonardo de Araujo, Stephan Pleschka, Michael Steinert, Robert Geffers, and Frank Pessler. Differential transcriptomic host responses in the early phase of viral and bacterial infections in human lung tissue explants ex vivo. Respiratory Research, Oct 2024. URL: https://doi.org/10.1186/s12931-024-02988-8, doi:10.1186/s12931-024-02988-8. This article has 9 citations and is from a domain leading peer-reviewed journal.

  9. (xu2024takingaimat pages 7-9): Dianne W. Xu and Michelle D. Tate. Taking aim at influenza: the role of the aim2 inflammasome. Viruses, 16:1535, Sep 2024. URL: https://doi.org/10.3390/v16101535, doi:10.3390/v16101535. This article has 6 citations.

  10. (sun2024mechanisticinsightsinto pages 10-11): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.

  11. (sun2024mechanisticinsightsinto pages 11-13): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.

  12. (qiu2024thrombosisincritically pages 2-3): Xianming Qiu, Mingjie Liu, Quanzhen Wang, Yuke Zhang, Li Kong, and Lei Zhou. Thrombosis in critically ill influenza patients: incidence and risk factors. Clinical and Applied Thrombosis/Hemostasis, Jan 2024. URL: https://doi.org/10.1177/10760296241278615, doi:10.1177/10760296241278615. This article has 3 citations.

  13. (thwaites2023earlymucosalevents pages 9-10): Ryan S. Thwaites, Ashley S. S. Uruchurtu, Victor Augusti Negri, Megan E. Cole, Nehmat Singh, Nelisa Poshai, David Jackson, Katja Hoschler, Tina Baker, Ian C. Scott, Xavier Romero Ros, Emma Suzanne Cohen, Maria Zambon, Katrina M. Pollock, Trevor T. Hansel, and Peter J. M. Openshaw. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43842-7, doi:10.1038/s41467-023-43842-7. This article has 56 citations and is from a highest quality peer-reviewed journal.

  14. (thwaites2023earlymucosalevents pages 2-2): Ryan S. Thwaites, Ashley S. S. Uruchurtu, Victor Augusti Negri, Megan E. Cole, Nehmat Singh, Nelisa Poshai, David Jackson, Katja Hoschler, Tina Baker, Ian C. Scott, Xavier Romero Ros, Emma Suzanne Cohen, Maria Zambon, Katrina M. Pollock, Trevor T. Hansel, and Peter J. M. Openshaw. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43842-7, doi:10.1038/s41467-023-43842-7. This article has 56 citations and is from a highest quality peer-reviewed journal.

  15. (thwaites2023earlymucosalevents pages 1-2): Ryan S. Thwaites, Ashley S. S. Uruchurtu, Victor Augusti Negri, Megan E. Cole, Nehmat Singh, Nelisa Poshai, David Jackson, Katja Hoschler, Tina Baker, Ian C. Scott, Xavier Romero Ros, Emma Suzanne Cohen, Maria Zambon, Katrina M. Pollock, Trevor T. Hansel, and Peter J. M. Openshaw. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43842-7, doi:10.1038/s41467-023-43842-7. This article has 56 citations and is from a highest quality peer-reviewed journal.

  16. (cai2024realworldeffectivenessand pages 1-2): Jianpeng Cai, Hongyu Wang, Xiaoting Ye, Shengjia Lu, Zhili Tan, Zhonghua Li, Dan Lin, Jiancheng Qian, Xiaoxian Lu, Jiaolong Wan, Jie Wang, Jingwen Ai, Yonglan Pu, Lihong Qu, and Sen Wang. Real-world effectiveness and safety of baloxavir marboxil or oseltamivir in outpatients with uncomplicated influenza a: an ambispective, observational, multi-center study. Frontiers in Microbiology, Jul 2024. URL: https://doi.org/10.3389/fmicb.2024.1428095, doi:10.3389/fmicb.2024.1428095. This article has 11 citations and is from a peer-reviewed journal.

  17. (cai2024realworldeffectivenessand media 252c64e8): Jianpeng Cai, Hongyu Wang, Xiaoting Ye, Shengjia Lu, Zhili Tan, Zhonghua Li, Dan Lin, Jiancheng Qian, Xiaoxian Lu, Jiaolong Wan, Jie Wang, Jingwen Ai, Yonglan Pu, Lihong Qu, and Sen Wang. Real-world effectiveness and safety of baloxavir marboxil or oseltamivir in outpatients with uncomplicated influenza a: an ambispective, observational, multi-center study. Frontiers in Microbiology, Jul 2024. URL: https://doi.org/10.3389/fmicb.2024.1428095, doi:10.3389/fmicb.2024.1428095. This article has 11 citations and is from a peer-reviewed journal.

  18. (kayesh2024recentinsightsinto pages 8-10): Mohammad Enamul Hoque Kayesh, Michinori Kohara, and Kyoko Tsukiyama-Kohara. Recent insights into the molecular mechanisms of the toll-like receptor response to influenza virus infection. International Journal of Molecular Sciences, 25:5909, May 2024. URL: https://doi.org/10.3390/ijms25115909, doi:10.3390/ijms25115909. This article has 15 citations.

  19. (sohail2024differentialtranscriptomichost pages 8-10): Aaqib Sohail, Fakhar H. Waqas, Peter Braubach, Laurien Czichon, Mohamed Samir, Azeem Iqbal, Leonardo de Araujo, Stephan Pleschka, Michael Steinert, Robert Geffers, and Frank Pessler. Differential transcriptomic host responses in the early phase of viral and bacterial infections in human lung tissue explants ex vivo. Respiratory Research, Oct 2024. URL: https://doi.org/10.1186/s12931-024-02988-8, doi:10.1186/s12931-024-02988-8. This article has 9 citations and is from a domain leading peer-reviewed journal.

  20. (xu2024takingaimat pages 2-4): Dianne W. Xu and Michelle D. Tate. Taking aim at influenza: the role of the aim2 inflammasome. Viruses, 16:1535, Sep 2024. URL: https://doi.org/10.3390/v16101535, doi:10.3390/v16101535. This article has 6 citations.

  21. (xu2024takingaimat pages 1-2): Dianne W. Xu and Michelle D. Tate. Taking aim at influenza: the role of the aim2 inflammasome. Viruses, 16:1535, Sep 2024. URL: https://doi.org/10.3390/v16101535, doi:10.3390/v16101535. This article has 6 citations.

  22. (xu2024takingaimat pages 5-7): Dianne W. Xu and Michelle D. Tate. Taking aim at influenza: the role of the aim2 inflammasome. Viruses, 16:1535, Sep 2024. URL: https://doi.org/10.3390/v16101535, doi:10.3390/v16101535. This article has 6 citations.

  23. (sun2024mechanisticinsightsinto pages 4-6): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.

  24. (sun2024mechanisticinsightsinto pages 6-8): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.

  25. (sun2024mechanisticinsightsinto pages 8-10): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.

  26. (marchenko2024endothelialactivationand pages 12-13): Vladimir A. Marchenko and Irina N. Zhilinskaya. Endothelial activation and dysfunction caused by influenza a virus (alphainfluenzavirus influenzae). Voprosy virusologii, 69 6:465-478, Dec 2024. URL: https://doi.org/10.36233/0507-4088-264, doi:10.36233/0507-4088-264. This article has 9 citations.

  27. (cai2024realworldeffectivenessand media b5b8ace7): Jianpeng Cai, Hongyu Wang, Xiaoting Ye, Shengjia Lu, Zhili Tan, Zhonghua Li, Dan Lin, Jiancheng Qian, Xiaoxian Lu, Jiaolong Wan, Jie Wang, Jingwen Ai, Yonglan Pu, Lihong Qu, and Sen Wang. Real-world effectiveness and safety of baloxavir marboxil or oseltamivir in outpatients with uncomplicated influenza a: an ambispective, observational, multi-center study. Frontiers in Microbiology, Jul 2024. URL: https://doi.org/10.3389/fmicb.2024.1428095, doi:10.3389/fmicb.2024.1428095. This article has 11 citations and is from a peer-reviewed journal.

  28. (acocaljuarez2024baloxavirresistancemarkers pages 2-4): Erick Acocal-Juárez, Luis Márquez-Domínguez, Verónica Vallejo-Ruíz, Lilia Cedillo, and Gerardo Santos-López. Baloxavir resistance markers in influenza a and b viruses in the americas. Drug, Healthcare and Patient Safety, 16:105-113, Sep 2024. URL: https://doi.org/10.2147/dhps.s470868, doi:10.2147/dhps.s470868. This article has 2 citations and is from a peer-reviewed journal.

  29. (acocaljuarez2024baloxavirresistancemarkers pages 4-7): Erick Acocal-Juárez, Luis Márquez-Domínguez, Verónica Vallejo-Ruíz, Lilia Cedillo, and Gerardo Santos-López. Baloxavir resistance markers in influenza a and b viruses in the americas. Drug, Healthcare and Patient Safety, 16:105-113, Sep 2024. URL: https://doi.org/10.2147/dhps.s470868, doi:10.2147/dhps.s470868. This article has 2 citations and is from a peer-reviewed journal.

  30. (acocaljuarez2024baloxavirresistancemarkers pages 7-9): Erick Acocal-Juárez, Luis Márquez-Domínguez, Verónica Vallejo-Ruíz, Lilia Cedillo, and Gerardo Santos-López. Baloxavir resistance markers in influenza a and b viruses in the americas. Drug, Healthcare and Patient Safety, 16:105-113, Sep 2024. URL: https://doi.org/10.2147/dhps.s470868, doi:10.2147/dhps.s470868. This article has 2 citations and is from a peer-reviewed journal.

  31. (clark2024recentadvancesin pages 12-14): Tristan W. Clark, John S. Tregoning, Helen Lister, Tiziano Poletti, Femy Amin, and Jonathan S. Nguyen-Van-Tam. Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials. Clinical Microbiology Reviews, Dec 2024. URL: https://doi.org/10.1128/cmr.00025-24, doi:10.1128/cmr.00025-24. This article has 12 citations and is from a highest quality peer-reviewed journal.

  32. (clark2024recentadvancesin pages 25-27): Tristan W. Clark, John S. Tregoning, Helen Lister, Tiziano Poletti, Femy Amin, and Jonathan S. Nguyen-Van-Tam. Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials. Clinical Microbiology Reviews, Dec 2024. URL: https://doi.org/10.1128/cmr.00025-24, doi:10.1128/cmr.00025-24. This article has 12 citations and is from a highest quality peer-reviewed journal.

  33. (clark2024recentadvancesin pages 19-22): Tristan W. Clark, John S. Tregoning, Helen Lister, Tiziano Poletti, Femy Amin, and Jonathan S. Nguyen-Van-Tam. Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials. Clinical Microbiology Reviews, Dec 2024. URL: https://doi.org/10.1128/cmr.00025-24, doi:10.1128/cmr.00025-24. This article has 12 citations and is from a highest quality peer-reviewed journal.

  34. (sun2024mechanisticinsightsinto pages 1-2): Yuling Sun and Kaituo Liu. Mechanistic insights into influenza a virus-induced cell death and emerging treatment strategies. Veterinary Sciences, 11:555, Nov 2024. URL: https://doi.org/10.3390/vetsci11110555, doi:10.3390/vetsci11110555. This article has 14 citations.